acamprosate vs aripiprazole
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of acamprosate and aripiprazole. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Campral
Abilify
Acamprosate is a medicine that can help you stay away from alcohol if you are alcohol-dependent and have already stopped drinking. It should be used with counseling and support.
Aripiprazole (Abilify) is a medicine used to treat certain mental disorders and mood problems. It can help to improve your mood, thinking, and behavior.
Acamprosate helps people who are alcohol-dependent to not drink alcohol. You must have already stopped drinking before you start taking acamprosate. This medicine works best when it is part of a complete treatment plan that includes counseling and support.
Aripiprazole is used to treat schizophrenia in adults and teens. It also treats irritability in children with autism. Additionally, it can treat Tourette's disorder.
Acamprosate is similar to a natural substance in your brain. It is thought to work by helping to restore the normal balance of brain activity that is changed by long-term alcohol use. This can reduce your craving for alcohol.
Aripiprazole works by affecting the levels of certain chemicals in the brain. These chemicals, like dopamine and serotonin, can affect mood and behavior. By balancing these chemicals, aripiprazole helps to reduce symptoms of mental health conditions.
- • Accidental injury
- • Weakness
- • Pain
- • Loss of appetite
- • Diarrhea
- • Nausea
- • Vomiting
- • Constipation
- • Headache
- • Dizziness
- Hypotension 14
- Asthenia 13
- Condition Aggravated 13
- Acute Kidney Injury 12
- Coma 12
- Weight Increased 7,698
- Anxiety 4,993
- Fatigue 4,188
- Suicidal Ideation 3,991
- Depression 3,950
Acamprosate may increase the risk of suicidal thoughts or actions. Your doctor should watch you for depression or suicidal thoughts. Tell your doctor right away if you have any new or worsening symptoms of depression or suicidal thoughts.
Aripiprazole may increase the risk of death in elderly patients who have psychosis related to dementia. It is not approved for this use. Antidepressants may increase the risk of suicidal thoughts and behaviors in children, teens, and young adults. Watch closely for worsening mood or suicidal thoughts.
Acamprosate may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if acamprosate passes into breast milk. Talk to your doctor if you are breastfeeding.
If you are pregnant or plan to become pregnant, talk to your doctor. Aripiprazole may cause withdrawal symptoms or other problems in newborns if taken during the third trimester. There is a pregnancy registry for women who take aripiprazole during pregnancy.
Also Compare, Nearby Drugs
Compare aripiprazole with
How to Read This acamprosate vs aripiprazole Comparison
acamprosate is classified in the GABA Analog (Alcohol Dependence) drug class, while aripiprazole sits within the Atypical Antipsychotic class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, acamprosate has 64 submissions while aripiprazole has 24,820. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for acamprosate or aripiprazole.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.